Introduction: Multiple endocrine and metabolic abnormalities, particularly overweight and obesity, have emerged as significant global public health concerns. This paper examines the impact of these conditions on health outcomes and underscores the necessity for comprehensive strategies to address them. Background: Overweight and obesity have been observed in patients with human immunodeficiency virus (HIV) both before and after the initiation of antiretroviral therapy. This study investigates the risk factors associated with overweight and obesity in HIV-infected patients. Methods: A total of 492 HIV-infected patients, both treatment-na?ve and those undergoing treatment, were recruited from Yaoundé Central Hospital in Cameroon. Demographic, anthropometric, and biochemical data were collected from each patient. Blood pressure and abdominal fat measurements were also taken. Metabolic syndrome was defined according to IDF criteria. Patients were categorized into two weight status groups: underweight/normal weight and overweight/obese. Results: The prevalence of overweight and obesity was found to be 27.5% and 8.5%, respectively, with only 6.1% of patients being underweight. Abdominal obesity, systolic/diastolic blood pressure, metabolic syndrome, and CD4 cell counts were associated with risk factors in overweight and obese patients. These parameters should be considered when investigating metabolic disorders in HIV-infected patients, as in the general population. Conclusion: Our study indicates a high risk of developing metabolic syndrome among overweight/obese individuals, who were 5.7 times more likely to have metabolic syndrome compared to those of normal weight/underweight. These findings support the hypothesis that overweight and obesity are also prevalent in HIV-infected patients and they are risk factors that have to be taken into consideration to better manage this issue. These results may provide essential information on the fact that being underweight is not the only issue to take into consideration in these patients but that overweight/obesity is now present. Prevention and management strategies should consider both aspects.
References
[1]
WHO (2020) Obesity and Overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[2]
Choukem, S., Tochie, J.N., Sibetcheu, A.T., Nansseu, J.R. and Hamilton-Shield, J.P. (2020) Overweight/Obesity and Associated Cardiovascular Risk Factors in Sub-Saharan African Children and Adolescents: A Scoping Review. InternationalJournalofPediatricEndocrinology, 2020, Article No. 6. https://doi.org/10.1186/s13633-020-0076-7
[3]
Omar, S.M., Taha, Z., Hassan, A.A., Al-Wutayd, O. and Adam, I. (2020) Prevalence and Factors Associated with Overweight and Central Obesity among Adults in the Eastern Sudan. PLOSONE, 15, e0232624. https://doi.org/10.1371/journal.pone.0232624
[4]
van Wijk, J.P.H. and Cabezas, M.C. (2012) Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. InternationalJournalofVascularMedicine, 2012, Article ID: 201027. https://doi.org/10.1155/2012/201027
[5]
Krishnan, S., Schouten, J.T., Atkinson, B., Brown, T., Wohl, D., McComsey, G.A., et al. (2012) Metabolic Syndrome before and after Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals. JAIDSJournalofAcquiredImmuneDeficiencySyndromes, 61, 381-389. https://doi.org/10.1097/qai.0b013e3182690e3c
[6]
Bailin, S.S., Gabriel, C.L., Wanjalla, C.N. and Koethe, J.R. (2020) Obesity and Weight Gain in Persons with HIV. CurrentHIV/AIDSReports, 17, 138-150. https://doi.org/10.1007/s11904-020-00483-5
[7]
Kumar, S. and Samaras, K. (2018) The Impact of Weight Gain during HIV Treatment on Risk of Pre-Diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. FrontiersinEndocrinology, 9, Article No. 705. https://doi.org/10.3389/fendo.2018.00705
[8]
Saito, A., Karama, M. and Kamiya, Y. (2020) HIV Infection, and Overweight and Hypertension: A Cross-Sectional Study of HIV-Infected Adults in Western Kenya. TropicalMedicineandHealth, 48, Article No. 31. https://doi.org/10.1186/s41182-020-00215-w
[9]
Anyabolu, E.N. (2016) BMI and Risk Factors of Underweight and Obesity in HIV Subjects in Eastern Nigeria. WorldJournalofAids, 6, 8-15. https://doi.org/10.4236/wja.2016.61002
[10]
Magnani, R. (1997) Sampling Guide. Food and Nutrition Technical Assistance, 52 p.
[11]
Institut National de la Statistique (INS) (2011) Cameroon-Enquête Démographique et de Santé et à Indicateurs Multiples. https://microdata.worldbank.org/index.php/catalog/1564
[12]
(2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. ObesityandMetabolism, 2, 47-49. https://doi.org/10.14341/2071-8713-4854
[13]
Trinder, P. (1969) Determination of Blood Glucose Using an Oxidase-Peroxidase System with a Non-Carcinogenic Chromogen. JournalofClinicalPathology, 22, 158-161. https://doi.org/10.1136/jcp.22.2.158
[14]
Allain, C.C., Poon, L.S., Chan, C.S.G., Richmond, W. and Fu, P.C. (1974) Enzymatic Determination of Total Serum Cholesterol. ClinicalChemistry, 20, 470-475. https://doi.org/10.1093/clinchem/20.4.470
[15]
Fossati, P. and Prencipe, L. (1982) Serum Triglycerides Determined Colorimetrically with an Enzyme That Produces Hydrogen Peroxide. ClinicalChemistry, 28, 2077-2080. https://doi.org/10.1093/clinchem/28.10.2077
[16]
Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. ClinicalChemistry, 18, 499-502. https://doi.org/10.1093/clinchem/18.6.499
[17]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: TheJournaloftheAmericanMedicalAssociation, 285, 2486-2497. https://doi.org/10.1001/jama.285.19.2486
[18]
Mandob, D.E. and Ombolo, A.A. (2017) Prevalence of Metabolic Syndrome among Civil Servants Women Yaoundé—Cameroon. WorldJournalofPharmacyandPharmaceuticalSciences, 6, 111-119. https://doi.org/10.20959/wjpps20174-8802
[19]
Souza, S.J., Luzia, L.A., Santos, S.S. and Rondó, P.H.C. (2013) Lipid Profile of HIV-Infected Patients in Relation to Antiretroviral Therapy: A Review. RevistadaAssociaçãoMédicaBrasileira, 59, 186-198. https://doi.org/10.1016/j.ramb.2012.11.003
[20]
Haugaard, S.B., Andersen, O., Pedersen, S.B., Dela, F., Fenger, M., Richelsen, B., et al. (2006) Tumor Necrosis Factor Α Is Associated with Insulin-Mediated Suppression of Free Fatty Acids and Net Lipid Oxidation in HIV-Infected Patients with Lipodystrophy. Metabolism, 55, 175-182. https://doi.org/10.1016/j.metabol.2005.08.018
[21]
Chukwuonye, I.I., et al. (2013) Prevalence of Overweight and Obesity in Adult Nigerians—A Systematic Review. Diabetes, MetabolicSyndromeandObesity: TargetsandTherapy, 6, 43-47. https://doi.org/10.2147/dmso.s38626
[22]
Darsini, D., Hamidah, H., Notobroto, H.B. and Cahyono, E.A. (2020) Health Risks Associated with High Waist Circumference: A Systematic Review. JournalofPublicHealthResearch, 9, 1811-1817. https://doi.org/10.4081/jphr.2020.1811
[23]
Adeoye, I., Aridegbe, M. and Oguntade, A. (2019) Obesity, Hypertension, and Dyslipidemia among Human Immunodeficiency Virus Patients in Abeokuta Ogun State, Nigeria. NigerianJournalofCardiology, 16, 83-91. https://doi.org/10.4103/njc.njc_10_18
[24]
Fahme, S.A., Bloomfield, G.S. and Peck, R. (2018) Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms. Hypertension, 72, 44-55. https://doi.org/10.1161/hypertensionaha.118.10893
[25]
Adébayo, A., Comlan, D.A., Ericie, S., Angelo, A., Jules, G., Armand, W., et al. (2015) Prévalence, facteurs associés et prédisposant du syndrome métabolique chez les personnes vivants avec le VIH sous traitement antirétroviral à Porto-Novo en 2014. PanAfricanMedicalJournal, 22, 296. https://doi.org/10.11604/pamj.2015.22.296.7923
[26]
Rogalska-Płońska, M., Grzeszczuk, A., Rogalski, P., Łucejko, M. and Flisiak, R. (2018) Metabolic Syndrome in HIV Infected Adults in Poland. KardiologiaPolska, 76, 548-553. https://doi.org/10.5603/kp.a2017.0249
[27]
Dimodi, H.T., Etame, L.S., Nguimkeng, B.S., Mbappe, F.E., Ndoe, N.E., Tchinda, J.N., et al. (2014) Prevalence of Metabolic Syndrome in HIV-Infected Cameroonian Patients. WorldJournalofAIDS, 4, 85-92. https://doi.org/10.4236/wja.2014.41011
[28]
Bourgi, K., Rebeiro, P.F., Turner, M., Castilho, J.L., Hulgan, T., Raffanti, S.P., et al. (2019) Greater Weight Gain in Treatment-Naive Persons Starting Dolutegravir-Based Antiretroviral Therapy. ClinicalInfectiousDiseases, 70, 1267-1274. https://doi.org/10.1093/cid/ciz407
[29]
Castro, A.d.C.O., Silveira, E.A., Falco, M.d.O., Nery, M.W. and Turchi, M.D. (2016) Overweight and Abdominal Obesity in Adults Living with HIV/Aids. RevistadaAssociaçãoMédicaBrasileira, 62, 353-360. https://doi.org/10.1590/1806-9282.62.04.353